We presented a study in patients with resected pancreatic cancer.
It’s a co-operative trial between the PRODIGE group in France and the CCTG Canadian Research Group.
We have included 493 patients with resected pancreatic cancer and we compared the standard of care, gemcitabine for six months, to modified FOLFIRINOX for also six months.
We performed an intent to treat analysis after the inclusion of 493 patients.
The main result of this study is an increased toxicity in the FOLFIRINOX group but it’s still a manageable treatment and I would like to stress the DFS results which are impressive because at three years we had a 21% DFS rate in the gemcitabine group and it’s nearly 40% in the FOLFIRINOX group.
This translated to a large difference in median survival which was 35 months in the gemcitabine group and 54.4 months in the FOLFIRINOX group.
The benefit for FOLFIRINOX was seen in all subgroups and for all endpoints so FOLFIRINOX should be a new option and probably a standard of care in patients with resected pancreatic cancer and good performance status.